NephroGenex Announces Date of Conference Call to Discuss Third Quarter 2014 Financial Results

RESEARCH TRIANGLE PARK, N.C.--()--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its third quarter 2014 financial results on Wednesday, November 12, 2014 after the U.S. financial markets close. The Company will host a conference call the following day, Thursday, November 13, 2014 at 8 a.m. Eastern, to review the third quarter 2014 financial results and provide an update on its PIONEER program for diabetic nephropathy and milestones for the remainder of 2014.

To access the call, participants should dial (844) 831-3030 (U.S. domestic) and (315) 625-6887 (international) at least 10 minutes prior to the start of the call, using passcode 28276479. The event will be webcast live and can also be accessed on the Company’s website at http://nephrogenex.investorhq.businesswire.com/events-calendar. A replay will be available on the website with the same link approximately 2 hours after the event for 30 days.

About Diabetic Nephropathy

Diabetic nephropathy is a chronic, degenerative disease of the kidney caused by diabetes. There are approximately 6 million patients with diabetic nephropathy in the United States (approximately 33% of diagnosed diabetics). Patients suffering from diabetic nephropathy may progress to End Stage Renal Failure (and require dialysis) or death. There are currently no adequate treatments for this disease.

About Pyridorin®

Pyridorin inhibits pathogenic oxidative chemistries, which are collectively elevated in diabetic patients and induce pathological changes implicated in the development of diabetic nephropathy. Pyridorin inhibits a broad range of these chemistries which we believe accounts for its effectiveness in slowing the progression of nephropathy in diabetic patients as shown in our Phase 2 studies. Our lead drug candidate was found to be safe and well-tolerated in these same studies.

About NephroGenex, Inc.

NephroGenex (NASDAQ:NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of PYRIDORIN® (pyridoxamine dihydrochloride), which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.

Cautionary Note on Forward-Looking Statements

This press release contains certain statements that are, or may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements regarding the outlook for our future business and financial performance. Forward-looking statements are based on our current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from those in the forward-looking statements due to global political, economic, business, competitive, market, regulatory and other factors and risks, including the items identified under "Part I—Item 1A—Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission ("SEC") on March 31, 2014, as well as in other filings that we may make with the SEC in the future. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we do not undertake and specifically disclaim any obligation to update any forward-looking statements.

Contacts

Investors
The Trout Group
Michael Levitan, 646-378-2920
mlevitan@troutgroup.com
or
Media
BMC Communications
Susan Duffy, 646-513-3119
sduffy@bmccommunications.com

Contacts

Investors
The Trout Group
Michael Levitan, 646-378-2920
mlevitan@troutgroup.com
or
Media
BMC Communications
Susan Duffy, 646-513-3119
sduffy@bmccommunications.com